Israel-based OutSense Diagnostics is developing a small medical device that can be attached to a toilet bowl. The patented technology can be used to detect medical conditions by analyzing and diagnosing human waste. The device enables the identification of blood in the stool, which can be an indication of colorectal cancer, and the company was granted a patent in the US, Japan, Europe, and China for this application. The platform can also be used to detect urinary tract infections, IBS, dehydration, and diarrhea. Others use cases include personalized weight loss management, monitoring drug intake, and optimizing food supplements.
The device is equipped with a smart optical sensor that automatically scans human excreta. This information is transferred to its cloud-based platform, where it is analyzed using advanced imaging algorithms and AI technology. The analysis will take into account an individual’s medical history to provide personalized diagnosis and biofeedback. The results can be viewed by a user and their caregiver via the OutSense mobile app, while information is also directly accessible through an organization’s Health Information System.
Key customers and partnerships
The company will be piloting its product together with CommuniCare Family of Companies, Longevity's parent company, which operates more than 90 health care facilities in the US. OutSense is also conducting clinical trials in Israel and Japan.
Funding and financials
In June 2021, the company raised USD 2.7 million in a Series A funding round from Longevity Venture Partner, which were used for product development, production, and commercialization.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.